Meddenovo

The company develops Mexa, an AI-powered platform for the de novo design of cyclic peptides to discover next-generation therapeutics. The platform combines large-scale generation with physics-based evaluation to identify drug candidates for oncology, radiopharmaceuticals, and metabolic diseases. They provide these computational discovery services through internal programs and collaborations with industrial partners.